VAL 0417 / Valerion - LARVOL DELTA

Perturbed glycogen metabolism is an Alzheimer's disease therapeutic target (AAIC 2023) - "Multiple agents can decrease Aβ and tau levels, such as the recently FDA-approved Aducanumab. These studies suggest that targeting AD glycogen with VAL-0417, either alone or in combination with other therapies targeting Aβ and/or tau, is an exciting and novel preclinical therapeutic target."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia